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lab has suggested that LcrG interacts with LcrV throughDissecting the Structure of LcrV
a N-terminal domain in LcrG. The N-terminal domainfrom Yersinia pestis, a Truly of LcrG has features suggestive of  helix, including
a heptad repeat of hydrophobic residues (Matson andUnique Virulence Protein
Nilles, 2002). Based on mutational studies in lcrG to
disrupt the proposed N-terminal  helix Matson and
Nilles proposed that LcrG interacts with LcrV in a coiled-
Last month in the February issue, Structure published coil type of interaction (Matson and Nilles, 2002). The
the crystal structure of LcrV from Yersinia pestis, the results obtained by Lawton et al. are consistent with
infectious agent that causes plague. LcrV activity is this hypothesis and the studies with LcrG and LcrV com-
essential for disease, and the structure of this protein plement each other nicely. Perhaps the most striking
provides a valuable tool to dissect the nature of its aspect of the current study describes an intramolecular
pathogenicity. coiled-coil structure in LcrV between helices 7 and 12
(Figure 1 of Derewenda et al., 2004). The interaction
Yersinia pestis, the causative agent of plague, is respon- between 7 and 12 appears to be mediated by a unique
sible for over 200 million human deaths since the Plague hydrophobic “zipper” motif (Derewenda et al., 2004).
of Justinian in 541 A.D. Essential to the ability of Y. pestis Importantly, the residues in LcrV identified by Lawton
to cause disease is the activity of a type III secretion et al. are found in 7 and they are involved in the interac-
system. The net effect of the Y. pestis type III secretion tion of 7 with 12. This unique intramolecular coiled-
system and its secreted effectors is a blockade of the coil structure appears near the center of the LcrV crystal
innate immune response. On top of the activity of the structure (Figure 1 of Derewenda et al., 2004) and sug-
type III effectors within cells to suppress innate immunity gests that LcrG interacts with LcrV within this region.
is the activity of LcrV (a.k.a. the V antigen). LcrV is a Additional evidence to support this assertion is a result
multifunctional protein that is central to the activity of showing that the single cysteine in LcrG can be cross-
the type III secretion apparatus. LcrV activates effector linked to the single cysteine (position C273 that pre-
secretion by binding the negative regulator LcrG and is cedes 12) in LcrV by the sulfhydryl crosslinker BMH
essential along with Yops B and D to translocate the (Nilles et al., 1997). This ability to crosslink the cysteine
effectors into eukaryotic cells. In addition, LcrV medi- residues between LcrG and LcrV suggests that the two
ates a direct immune suppression by interaction with cysteine residues come within 16.1 A˚ of each other.
TLR2 to upregulate IL-10 levels by an unknown mecha- Unpublished work in my lab has identified a second
nism. Many groups, including mine, have worked to de- region of LcrV involved in the interaction with LcrG.
fine structure function relationships within LcrV; these Random linker insertion of five amino acid groups dem-
attempts have met with limited success. In the February onstrated that insertions after residues S277, T289, and
issue of Structure, Derewenda et al. describe the three S292 could disrupt the LcrV-LcrG interaction in a yeast
dimensional crystal structure of a mutant LcrV protein two-hybrid system. Subsequent site-directed mutagen-
(Derewenda et al., 2004). The description of the LcrV esis studies have suggested that residues L291 and
crystal structure will certainly allow a more focused ap- F308 are involved in the LcrV-LcrG interaction. L291 is
proach to LcrV structure-function studies, and the crys- involved in the 7-12 interaction (Figure 2 of Dere-
tal structure already provides some new insights into wenda et al., 2004) and is located very near the L160
LcrV function. and L164 residues identified by Lawton et al. F308 is
Recent structure function studies on LcrV have largely located further away from the “zipper” motif region and
focused on LcrV interactions with other proteins. In one should be located in or just after the kink in 12.
study a region of LcrV that appears to interact with TLR2 Collectively, the published and unpublished data that
to modulate the immune response was identified (Sing describe the region of LcrV involved with LcrG interac-
et al., 2002). Sing et al. describe the involvement of tion are supported by the crystal structure. The structure
residues 39–55 of LcrV in mediating the TLR2 interaction clearly shows that the two regions identified by muta-
(Sing et al., 2002). Interestingly, this region includes the tional studies physically interact with one another and
residues mutated in the current study that allowed LcrV suggest that the resultant structure is then involved in
crystallization (resides 40–42). Another relevant obser- the LcrG interaction. Clearly, the structure of LcrV will be
vation is that the region identified by Sing et al. seems invaluable to dissecting the functions of this extremely
to be surface exposed in the crystal structure and pre- interesting virulence protein.
cedes the unordered region located between 1 and
2 (Figure 1 of Derewenda et al., 2004). This surface
exposure would presumably allow interaction with TLR2.
Matthew L. NillesIn a second study, Lawton et al. (2002) describe a set
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consequence of the fact that the polyketide biosyntheticCofactors in Fatty Acid
pathways in organisms like streptomyces are closelyBiosynthesis—Active Site related and intersect with the fatty acid biosynthetic
pathways (Campbell and Cronan, 2001).Organizers and Drug Targets
The most recently determined structures of enzymes
in the FAS system have been the -ketoacyl-acyl carrier
protein reductase (FabG), which reduces the ACP-linked
-ketoacyl group to a -hydroxyacyl group. StructuresThe structure of E. coli -ketoacyl-acyl carrier protein
of this enzyme have been determined for the Brassicareductase (FabG) in its binary complex with NADPH
Napus (Fisher et al., 2000), M. tuberculosis (Cohen-Gon-reveals how cofactor-induced conformational changes
saud et al., 2002), and E. coli (Price et al., 2001, 2004configure the active site for catalysis. It provides an-
[this issue of Structure]) FabGs, all of which are compo-other target for drug design in the fatty acid biosynthe-
nents of type II FAS systems. FabG utilizes NADPH tosis pathway.
reduce the -keto group, and structures of the cofactor
binary complexes of Brassica Napus and E. coli en-It has been over 40 years since the components of the
zymes and of the apoenzymes of M. tuberculosis andfatty acid biosynthesis pathway were identified and 20
E. coli have been determined. In this issue of Structure,years since the detailed mechanisms of the steps of this
the structure of the binary cofactor complex of E. coliessential pathway in bacteria and eukarya were worked
FabG with NADP is described. Through comparison ofout. The multiple enzyme activities that catalyze the
this complex with the apoenzyme and with a point mu-steps of fatty acid synthesis, collectively called fatty
tant structure, a complex set of conformational changesacid synthase (FAS), are closely similar in all organisms
induced by cofactor binding is revealed. These changes
(Figure 1). Variations in fatty acid product profiles among
assemble the Ser-Tyr-Lys catalytic triad and also a water
organisms arise from altered reactant specificities of
chain that is adduced to play an essential role as a
the otherwise similar enzymes of the pathway, rather proton wire in restoring the catalytic conformation at
than from alternative pathways. The enzymes of the FAS the end of the reaction. These conformational changes
pathway exist in two forms, called I and II, which are also suggest a basis for the coordinated positive (acyl-
distinguished by the polypeptide chain connectivity of ACP) and negative (NADPH) cooperativity of the tetra-
the constituent enzymes. The type I FAS is an obligate meric FabG coupled to NADPH binding.
homodimer of multifunctional monomers, while the type It is noteworthy in this FabG binary complex structure
II FAS is composed of discrete enzymes that correspond that binding of the nucleotide and nicotinamide moieties
functionally, and probably also structurally, to the func- of NADPH are inferred to occur sequentially and that
tional domains of the type I FAS. The type I FAS occurs the participation of the NADP cofactor in catalysis is
in animals and yeast and the type II FAS predominates not limited to chemistry in the nicotinamide ring. The
in bacteria, though there are organisms (e.g., M. tuber- structure of the Tyr151Phe mutant in complex with
culosis) (Bloch, 1977) that carry both types of FAS. NADP shows that the nucleotide of NADP binds in the
In the past 10 years, representative structures of all same way as in the wild-type, but the nicotinamide and
enzymes and carrier proteins of type II FAS systems ribose groups are disordered. The implication is that the
have been determined. This recent interest in the struc- nucleotide binds first and subsequent conformational
tures of the FAS enzymes stems from the appreciation changes create the nicotinamide binding site and the
that the FAS system has several characteristics that catalytic configuration at the active site. Comparison of
make it an attractive target for drug design: indispens- the Tyr151Lys mutant binary complex structure with that
ability, preexisting bacteriostatic drugs (isoniazid, triclo- of the wild-type points to multiple critical roles for the
san) that target this pathway, and the distinction be- ribose hydroxyl groups of NADP in organizing the active
tween the animal type I and bacterial type II FASs, which site residues and in catalysis. These hydroxyl groups
offers the possibility of specificity in the design of anti- form hydrogen bonds to the Tyr151 and Lys155 residues
bacterials. There are relatively few natural product inhib- of the catalytic triad and also are part of the proton wire
itors of fatty acid biosynthesis (cerulenin, thiolac- extending from the ordered water chain that is essential
for catalytic turnover.tomycin), and it has been suggested that this is a
